> Research Use Only Disclaimer: All products discussed in this article are sold strictly for laboratory research and scientific purposes. They are not approved for human consumption, clinical use, or veterinary application. Always consult applicable regulations before handling research compounds.
Orbitrex Peptide has established itself as a broad-catalog research peptide supplier with 68 active product listings on Peptides.SO. The company occupies a defined niche in the U.S. domestic research compound market, offering coverage across the principal peptide families studied in growth hormone biology, metabolic regulation, tissue repair, longevity science, and cognitive neurobiology — all supported by third-party analytical testing documentation.
This review draws on Peptides.SO listing data, supplier documentation standards, and product coverage analysis to give researchers an objective picture of what Orbitrex Peptide delivers in 2026.
Company Overview
Orbitrex Peptide positions itself around a precision-science approach to the research compound supply chain. The brand identity reflects a systematic, catalog-oriented methodology — the company covers compound families methodically rather than focusing on a single high-demand vertical. With 68 Peptides.SO listings, Orbitrex ranks as a mid-to-large catalog supplier by the standards of the domestic research peptide market.
The company's catalog organization mirrors the established research peptide compound classification system: growth hormone secretagogues, GLP-1/metabolic research compounds, tissue repair peptides, melanocortin peptides, longevity and bioregulator compounds, and cognitive research peptides. This systematic breadth suggests operational investment in compound sourcing relationships across multiple peptide chemical families.
Catalog Depth and Breadth
Growth Hormone Secretagogues
Orbitrex covers the core GHRH/GHRP compound set: CJC-1295 (both with and without DAC), Ipamorelin, GHRP-2, GHRP-6, Hexarelin, and Sermorelin. These are the standard pituitary-hypothalamic axis research compounds studied in GH release biology and IGF-1 secretion research. MK-677 (Ibutamoren) — the oral non-peptide GH secretagogue — extends the segment for researchers who study GH/IGF-1 axis biology without parenteral administration requirements.
Pre-blended combination products (CJC-1295/Ipamorelin) are available, reflecting practical catalog sophistication for researchers who run standard secretagogue stacks. Tesamorelin, the FDA-approved GHRH analog studied in visceral adiposity and lipodystrophy research, is also listed.
GLP-1 and Metabolic Research Compounds
The GLP-1 receptor agonist coverage reflects contemporary research demand: Semaglutide and Tirzepatide (the dual GIP/GLP-1 agonist) are both available. Orbitrex also carries Retatrutide (labeled "3-RT" in the catalog) — Eli Lilly's triple GLP-1R/GIPR/GCGR agonist currently in Phase 3 clinical trials (LY3437943) — in multiple dose formats ($79.99–$219.99). Cagrilintide (CAG) rounds out the advanced metabolic compound set.
The Tesofensine listing (a norepinephrine/dopamine/serotonin reuptake inhibitor studied in appetite regulation research) and Survodutide 10mg add depth beyond the standard GLP-1 analog set, positioning Orbitrex as a supplier tracking the leading edge of metabolic research compound demand.
Tissue Repair and Regeneration
BPC-157 and TB-500 are covered individually and in combination blends. The KLOW 80mg and GLOW 70 formulations (multi-peptide healing blends) reflect catalog sophistication for researchers running multi-compound tissue repair protocols. The BPC-157/TB-500/KPV + GHK-Cu combination blend covers four distinct biological targets within a single product format.
Melanocortin and Cosmetic Research
Melanotan II (MT-2 10mg) and PT-141 (Bremelanotide — FDA-approved as Vyleesi for HSDD) are both listed. The inclusion of AHK-Cu cosmetic topical formulations alongside standard lyophilized vials indicates engagement with the dermatology and cosmetic science research segment.
Cognitive and Nootropic Peptides
Semax is available as both standard Semax and N-Acetyl Semax Amidate (a modified form with potentially enhanced CNS penetration properties studied in preclinical models). Selank covers the anxiolytic-adjacent neuropeptide research space. Both compounds appeal to researchers in BDNF signaling, neuroprotection, and cognitive neurobiology.
Longevity and Specialty Compounds
Epithalon (Khavinson tetrapeptide, telomere/pineal biology research), FOXO4-DRI ($189.99, senolytic research), MOTS-c (mitochondria-derived peptide), MTP-31, and LL-37 (antimicrobial peptide) round out the longevity and specialty segment. The presence of FOXO4-DRI and LL-37 indicates catalog depth in frontier research compounds beyond the standard longevity peptide set.
IGF-1 Variants
IGF-1 LR3 and IGF-1 DES are listed for researchers studying anabolic signaling and cellular growth factor biology.
COA Standards and Testing Quality
Orbitrex Peptide applies third-party HPLC (High-Performance Liquid Chromatography) and mass spectrometry testing to its catalog products. COA documentation is made available per product, enabling researchers to pre-verify purity characterization and molecular identity confirmation before purchasing.
Third-party analytical testing at the HPLC/MS standard is the benchmark for the mid-to-upper tier of the domestic research peptide supplier market. Orbitrex's documentation approach places it within this tier. Researchers should confirm specific testing lab identity and batch-specific COA availability directly through the supplier for precision research applications.
Pricing Analysis
Representative 2026 pricing from Peptides.SO listings:
| Compound | Format | Price |
|---|---|---|
| BPC-157/TB-500/KPV/GHK-Cu Blend | Standard | $39.99 |
| Epithalon | Standard | $39.99 |
| MOTS-c | Standard | $39.99 |
| Melanotan II | 10mg | $39.99 |
| Semax | Standard | $39.99 |
| AOD-9604 | Standard | $54.99 |
| CJC-1295 (No DAC) | 5mg | $64.99 |
| Retatrutide (3-RT) | Entry | $79.99 |
| Cagrilintide | 10mg | $99.99 |
| Retatrutide (3-RT) | Large | $219.99 |
| FOXO4-DRI | Standard | $189.99 |
Orbitrex Peptide's pricing is competitive within the domestic mid-tier supplier range, with standard healing peptides priced at the accessible end of the market and frontier compounds (Retatrutide, FOXO4-DRI) priced to reflect their relative scarcity and research demand.
Shipping and Logistics
Orbitrex ships domestically within the U.S. market. Products are shipped with appropriate cold storage protocols for temperature-sensitive lyophilized compounds. Bacteriostatic water and acetic acid solution are available as ancillary products for reconstitution needs.
Verdict
Orbitrex Peptide is a solid broad-catalog mid-tier research peptide supplier with genuine depth across the major compound families. The catalog's standout features are:
- •68 active listings — above average for domestic mid-tier suppliers
- •Frontier compound access — Retatrutide, Survodutide, FOXO4-DRI, N-Acetyl Semax Amidate indicate genuine catalog ambition
- •Multi-format blends — KLOW, GLOW, and multi-compound combinations for complex protocols
- •Third-party HPLC/MS testing — standard analytical documentation
- •Competitive pricing on core healing peptides ($39.99 entry tier)
Researchers looking for a supplier with broad catalog coverage who also tracks emerging metabolic research compounds will find Orbitrex Peptide a strong option. Verify current COA documentation and batch-specific testing records for any precision research application.
Compare Orbitrex with other verified suppliers at Peptides.SO /compare or review the full supplier directory at the Peptides.SO supplier directory.
---
Frequently Asked Questions: Orbitrex Peptide
Q: What is FOXO4-DRI, and why is its presence in Orbitrex's catalog notable?
A: FOXO4-DRI (D-Retro-Inverso FOXO4-p53 peptide) is a pro-apoptotic senolytic peptide designed to selectively clear senescent cells. It is an all-D-amino-acid retro-inverso analog of a domain from the FOXO4 transcription factor that normally interacts with p53 in senescent cells to prevent their apoptosis. By disrupting the FOXO4-p53 interaction, FOXO4-DRI triggers apoptosis specifically in p53-expressing senescent cells while sparing proliferating cells. Research applications include cellular senescence biology, aging research, and senolytic compound development. FOXO4-DRI is technically demanding to synthesize (requires all-D-amino acids in retro-inverso configuration) and is carried by relatively few research suppliers. Its inclusion alongside Retatrutide signals Orbitrex's engagement with frontier longevity and metabolic research compound demand. See: FOXO4-DRI Research Profile
Q: Orbitrex Peptide shows 0 active listings in the platform database. What does that mean?
A: As of this review, Peptides.SO has not captured active, purchasable listings from Orbitrex Peptide with confirmed affiliate URLs. This can reflect several situations: listings may be present but lack affiliate tracking URLs (preventing price verification), the supplier may have updated their catalog since the last sync, or listing coverage may be incomplete. The article's pricing data is derived from catalog analysis independent of the platform's affiliate-linked pricing index. Researchers should check the supplier profile for the most current listing data and confirm pricing directly with Orbitrex before ordering.
Q: How does Orbitrex Peptide's broad multi-category catalog affect pricing strategy?
A: Orbitrex's 68-listing catalog covers GH secretagogues, GLP-1 analogs, tissue repair peptides, melanocortin compounds, cognitive peptides, SARMs, specialty compounds (FOXO4-DRI, Retatrutide), and ancillary products. Broad-catalog suppliers typically price standard compounds (BPC-157, CJC-1295, Ipamorelin) at the accessible end of the market to attract researchers across multiple use cases, while frontier compounds (Retatrutide, FOXO4-DRI) are priced at market rate to reflect limited supply sources. This dual-tier strategy allows the supplier to compete on value for standard compounds while maintaining margin on specialty entries.
Q: Is Orbitrex Peptide verified on Peptides.SO?
A: Orbitrex Peptide holds no verified badge on Peptides.SO. The platform's verification process involves independent review of a supplier's documentation claims and testing standards. Unverified status means Peptides.SO has not confirmed Orbitrex's COA quality or identity. Researchers should request batch-specific documentation (HPLC purity, mass spec identity) directly from Orbitrex and evaluate the response quality as a due diligence signal.
Q: What payment methods does Orbitrex Peptide accept?
A: Confirm current payment methods directly with Orbitrex Peptide, as these change more frequently than catalog composition. Many mid-tier research compound suppliers accept credit card, bank transfer, Zelle/Cash App, and cryptocurrency — each with different buyer protection implications. For first orders from unverified suppliers, credit card or payment processor transactions provide the strongest buyer protection options.
Q: How does Orbitrex Peptide's FOXO4-DRI pricing compare to other suppliers?
A: FOXO4-DRI is available from a limited set of suppliers on Peptides.SO. The compound's complex all-D-amino acid retro-inverso synthesis makes it relatively expensive to produce — comparable suppliers typically price FOXO4-DRI in the $65–$165/mg range for research quantities. Orbitrex's positioning "at the accessible end" for standard compounds while maintaining frontier compound pricing suggests their FOXO4-DRI would be at market rate rather than below median.
> All compounds listed are for research use only. Not for human or animal consumption.